These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 28672809)
21. T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells. Liu H; Zhou BH; Qiu X; Wang HS; Zhang F; Fang R; Wang XF; Cai SH; Du J; Bu XZ Free Radic Biol Med; 2012 Dec; 53(12):2204-17. PubMed ID: 23085518 [TBL] [Abstract][Full Text] [Related]
22. Exosomes and cells from lung cancer pleural exudates transform LTC4 to LTD4, promoting cell migration and survival via CysLT1. Lukic A; Wahlund CJE; Gómez C; Brodin D; Samuelsson B; Wheelock CE; Gabrielsson S; Rådmark O Cancer Lett; 2019 Mar; 444():1-8. PubMed ID: 30508568 [TBL] [Abstract][Full Text] [Related]
23. Effect of Montelukast on Bronchopulmonary Dysplasia (BPD) and Related Mechanisms. Chen X; Zhang X; Pan J Med Sci Monit; 2019 Mar; 25():1886-1893. PubMed ID: 30862773 [TBL] [Abstract][Full Text] [Related]
24. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413 [TBL] [Abstract][Full Text] [Related]
25. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Maeba S; Ichiyama T; Ueno Y; Makata H; Matsubara T; Furukawa S Ann Allergy Asthma Immunol; 2005 Jun; 94(6):670-4. PubMed ID: 15984600 [TBL] [Abstract][Full Text] [Related]
26. Montelukast inhibits interleukin-5 mRNA expression and cysteinyl leukotriene production in ragweed and mite-stimulated peripheral blood mononuclear cells from patients with asthma. Frieri M; Therattil J; Wang SF; Huang CY; Wang YC Allergy Asthma Proc; 2003; 24(5):359-66. PubMed ID: 14619337 [TBL] [Abstract][Full Text] [Related]
27. Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Nadeem A; Obiefuna PC; Wilson CN; Mustafa SJ Eur J Pharmacol; 2006 Dec; 551(1-3):116-24. PubMed ID: 17027749 [TBL] [Abstract][Full Text] [Related]
28. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer. Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309 [TBL] [Abstract][Full Text] [Related]
29. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Yu GL; Wei EQ; Zhang SH; Xu HM; Chu LS; Zhang WP; Zhang Q; Chen Z; Mei RH; Zhao MH Pharmacology; 2005 Jan; 73(1):31-40. PubMed ID: 15452361 [TBL] [Abstract][Full Text] [Related]
30. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474 [TBL] [Abstract][Full Text] [Related]
31. Cysteinyl leukotriene receptor 1 promotes 5-fluorouracil resistance and resistance-derived stemness in colon cancer cells. Satapathy SR; Sjölander A Cancer Lett; 2020 Sep; 488():50-62. PubMed ID: 32474153 [TBL] [Abstract][Full Text] [Related]
32. Leukotriene Receptor Antagonists Inhibit Mitogenic Activity in Triple Negative Breast Cancer Cells. Suknuntha K; Yubolphan R; Krueaprasertkul K; Srihirun S; Sibmooh N; Vivithanaporn P Asian Pac J Cancer Prev; 2018 Mar; 19(3):833-837. PubMed ID: 29582642 [TBL] [Abstract][Full Text] [Related]
33. Effect of the leukotriene receptor antagonist montelukast on orthodontic tooth movement. Asaad H; Al-Sabbagh R; Al-Tabba D; Kujan O J Oral Sci; 2017; 59(2):297-302. PubMed ID: 28637990 [TBL] [Abstract][Full Text] [Related]
34. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. Hoxha M; Rovati GE; Cavanillas AB Eur J Clin Pharmacol; 2017 Jul; 73(7):799-809. PubMed ID: 28374082 [TBL] [Abstract][Full Text] [Related]
35. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist. Tuğtepe H; Sener G; Cetinel S; Velioğlu-Oğünç A; Yeğen BC Eur J Pharmacol; 2007 Feb; 557(1):69-75. PubMed ID: 17173892 [TBL] [Abstract][Full Text] [Related]
36. Montelukast exerts no acute direct effect on NO synthases. Hamacher J; Eichert K; Braun C; Grebe T; Strub A; Lucas R; Eltze M; Wendel A Pulm Pharmacol Ther; 2007; 20(5):525-33. PubMed ID: 16815057 [TBL] [Abstract][Full Text] [Related]
37. Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast. Sener G; Sakarcan A; Sehirli O; Ekşioğlu-Demiralp E; Sener E; Ercan F; Gedik N; Yeğen BC Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):257-67. PubMed ID: 17499745 [TBL] [Abstract][Full Text] [Related]
38. The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. Cikler E; Ersoy Y; Cetinel S; Ercan F Acta Histochem; 2009; 111(2):112-8. PubMed ID: 18617226 [TBL] [Abstract][Full Text] [Related]
40. Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone. Murai A; Abe M; Hayashi Y; Sakata N; Katsuragi T; Tanaka K J Pharmacol Exp Ther; 2005 Feb; 312(2):432-40. PubMed ID: 15470084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]